MedTrace Logo

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

NCT00064623 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2008-03-06

No results posted yet for this study

Summary

The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is effective in treating painful HIV-associated neuropathy.

Conditions

  • HIV Infections
  • Peripheral Nervous System Diseases
  • Pain

Interventions

DRUG

Capsaicin Dermal Patch

Sponsors & Collaborators

  • NeurogesX

    lead INDUSTRY

Principal Investigators

  • David M Simpson, MD · Icahn School of Medicine at Mount Sinai

  • Jeffrey Tobias, MD · NeurogesX

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2005-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00064623 on ClinicalTrials.gov